Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer

Citation
A. Rydh et al., Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer, SC J UROL N, 33(2), 1999, pp. 89-93
Citations number
18
Categorie Soggetti
Urology & Nephrology
Journal title
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
ISSN journal
00365599 → ACNP
Volume
33
Issue
2
Year of publication
1999
Pages
89 - 93
Database
ISI
SICI code
0036-5599(199904)33:2<89:PVOPAT>2.0.ZU;2-J
Abstract
Objective: In order to evaluate the negative predictive value of a low pros tate-specific antigen (PSA) for a positive bone scan, we performed a retros pective study in a patient material from the Umea region in Northern Sweden . We also evaluated whether different tumour grades could influence this pr edictive value. Material and Methods: Four-hundred-and-forty-six patients o f newly diagnosed prostate cancer were reviewed. We analysed different leve ls of PSA, tumour grade, tumour stage and combinations of these parameters for their use in making a positive bone scintigraphy (BS) prediction. Resul ts: Among 214 patients with PSA <20 ng/ml, 9 showed a positive BS. When tum ours of grades 2 and 3 were excluded, the number of positive BS predictions decreased to 6. For 350 of these 446 patients, a classification according to TNM was available; 162 of these 350 had a PSA value <20 ng/ml, and when this group comprised only small and well-differentiated tumours (T1-2, G1), only one of the remaining 81 patients had a positive BS result. Conclusion s: We conclude that in most patients with small and well-differentiated tum ours (T1-2, G1) and PSA <20, BS staging need not be carried out.